PBAC's latest decision on 21-valent pneumococcal conjugate vaccine: Recommended with restriction (2025). Considered for Prevention of pneumococcal disease in non-Indigenous adults aged ≥70 years (or ≥65 years per ATAGI recommendation), Aboriginal and Torres Strait Islander adults aged ≥25 years, and adults aged ≥18 years with specified medical risk conditions.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Non-Indigenous adults aged ≥70 years; Aboriginal and Torres Strait Islander adults aged ≥25 years; adults aged ≥18 years with specified medical risk conditions (asplenia, immunocompromising conditions, chronic respiratory disease, chronic renal disease, CSF leak, cochlear implants, intracranial shunts, or prior invasive pneumococcal disease).
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Immunogenicity (serotype-specific opsonophagocytic responses and IgG responses)
Comparator
13-valent pneumococcal conjugate vaccine (13vPCV); near-market comparators: 15vPCV and 20vPCV
Economic model
CUA
ICER note
Cost-utility analysis (CUA) and cost-minimisation analysis (CMA) performed; numeric ICER values not stated in public document. For Aboriginal and Torres Strait Islander adults aged 25-49 years, cost-minimisation approach used versus 20vPCV.